Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.

Roberto CaporaliPeter C TaylorDaniel AletahaRaimon SanmartíTsutomu TakeuchiDaojun MoEwa HaladyjNatalia BelloLiliana Zaremba-PechmannYing FangMaxime Dougados

Published in: Rheumatology (Oxford, England) (2024)

Treatment with baricitinib 4 mg or 2 mg demonstrated efficacy up to 6.5 years with maintained LDA/remission results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated.

Keyphrases

rheumatoid arthritis
disease activity
high intensity
combination therapy
big data
ankylosing spondylitis
ulcerative colitis